- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Catalyst Pharmaceuticals Inc (CPRX)
The Catalyst Pharmaceuticals share price today is 28.240, view NASDAQ CPRX stock exchange data. Track the latest Catalyst Pharmaceuticals share price with real-time updates on CPRX stock performance including market cap, day range, 52-week range and dividend yield. Access CPRX charts, earnings dates and analyst estimates to support your investment decisions.
28.240
-0.020(-0.07%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.978
28.490
52 wk Range
19.050
32.560
Earnings results expected in 13 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.97828.490
52 wk Range
19.05032.560
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CPRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
34.000
Upside
+20.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.000
(+20.40% Upside)
Catalyst Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of $0.68 beat forecast of $0.31 by 119%; revenue reached $152.6M vs. $141.49M expected, up 7.6% year-over-year.
- Full-year 2025 revenue hit $589M, up 19.8% from 2024; GAAP net income rose 30.8% to $214.3M, driven by Firdapse and AGAMREE growth.
- Stock declined 0.52% in premarket despite earnings beat, following prior 3.3% drop; shares up 20.8% over past year with strong cash position.
- 2026 guidance projects Firdapse revenue growth of 21.4%-25.6% and AGAMREE growth of 19.6%-28.1%, supported by market expansion efforts.
- Key risks include generic competition affecting Fycompa, potential market saturation, and regulatory challenges impacting pricing and reimbursement.
Last Updated: 26-02-2026, 08:18 pm
Read Full TranscriptEarnings
Latest Release
25-02-2026
EPS / Forecast
0.68 / 0.31
Revenue / Forecast
152.6M / 141.49M
Compare CPRX to Peers and Sector
Metrics to compare | CPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.1x | 11.0x | −0.5x | |
PEG Ratio | 0.57 | −0.65 | 0.00 | |
Price/Book | 3.6x | 2.9x | 2.6x | |
Price / LTM Sales | 5.9x | 3.4x | 3.2x | |
Upside (Analyst Target) | 23.8% | 114.9% | 50.8% | |
Fair Value Upside | Unlock | 12.0% | 7.7% | Unlock |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Catalyst Pharmaceuticals (CPRX) Share Price Today?
The Catalyst Pharmaceuticals share price today is 28.240.
What is the current Catalyst Pharmaceuticals (CPRX) share price and day range?
As of 30-04-2026, the Catalyst Pharmaceuticals share price is 28.240, with a previous close of 28.260. The share price has ranged from 27.978 to 28.490 today, while the 52-week range spans from 19.050 to 32.560.
What Is the Catalyst Pharmaceuticals Market Cap?
As of today, Catalyst Pharmaceuticals market cap is 3.440B.
What Is the Catalyst Pharmaceuticals (CPRX) Share Price Target?
The average 12-month share price target for Catalyst Pharmaceuticals is 34.000, with a high estimate of 36 and a low estimate of 32. 7 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +20.40% Upside potential.
What Is Catalyst Pharmaceuticals's Earnings Per Share (TTM)?
The Catalyst Pharmaceuticals EPS (TTM) is 1.680.
When Is the Next Catalyst Pharmaceuticals Earnings Date?
Catalyst Pharmaceuticals will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is CPRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Catalyst Pharmaceuticals Trade On?
Catalyst Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Catalyst Pharmaceuticals?
The stock symbol for Catalyst Pharmaceuticals is "CPRX."
How Many Times Has Catalyst Pharmaceuticals Stock Split?
Catalyst Pharmaceuticals has split 0 times.
How Many Employees Does Catalyst Pharmaceuticals Have?
Catalyst Pharmaceuticals has 182 employees.
What Is the CPRX Premarket Price?
CPRX's last pre-market stock price is 28.310. The pre-market share volume is 3,510.000, and the stock has changed by 0.050, or 0.180%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.